Improving symptom control in early Parkinson's disease (Q34409267)

2 August 2017

Improving symptom control in early Parkinson's disease (English)

1 reference

2 August 2017

1 reference

2

Robert A Hauser

1 reference

2 August 2017

Stuart H Isaacson

1

1 reference

2 August 2017

1 November 2009

1 reference

Therapeutic advances in neurological disorders

2 August 2017

1 reference

2 August 2017

2

1 reference

2 August 2017

6

1 reference

2 August 2017

29-41

1 reference

Neuroimaging and transcranial ultrasonography in Parkinson's disease

2 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Invited Article: Nervous system pathology in sporadic Parkinson disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Serum urate as a predictor of clinical and radiographic progression in Parkinson disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Biomarkers for the early detection of Parkinson's and Alzheimer's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Valvular heart disease and the use of dopamine agonists for Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Fatigue in Parkinson's disease: a review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

The Parkinson's complex: parkinsonism is just the tip of the iceberg

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Non-motor symptoms of Parkinson's disease: diagnosis and management

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Frequency of bowel movements and the future risk of Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Risk factors for levodopa-induced dyskinesias in Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Parkinsonism: onset, progression, and mortality

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Treatment of parkinson's disease with bromocriptine

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind corssover analyses

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Modification of involuntary movements by centrally acting drugs

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Deprenyl in Parkinson's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Timing the initiation of treatment in Parkinson's disease

6 July 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609339383

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609339383

Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609339383

Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609339383

Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609339383

Levodopa-dyskinesia incidence by age of Parkinson's disease onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609339383

Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders?: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609339383

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609339383

Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609339383

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609339383

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609339383

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609339383

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609339383

Development of dyskinesias in a 5-year trial of ropinirole andL-dopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609339383

Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609339383

Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609339383

Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609339383

Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285609339383

The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002604

Selegiline slows the progression of the symptoms of Parkinson disease

27 October 2018

1 reference

12 December 2020

Agonist or levodopa for Parkinson disease?: ultimately, it doesn't matter; neither is good enough.

1 reference

12 December 2020

A double-blind controlled study of MK-486 in Parkinson's disease

1 reference

12 December 2020

Nonmotor fluctuations in Parkinson's disease: frequent and disabling

1 reference

12 December 2020

Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease

1 reference

12 December 2020

Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study

1 reference

12 December 2020

Nonmotor functions of the basal ganglia

1 reference

12 December 2020

1 reference

12 December 2020

Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group

1 reference

12 December 2020

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group

1 reference

12 December 2020

Detection and assay of dopamine

1 reference

12 December 2020

Impact of pramipexole on the onset of levodopa-related dyskinesias

1 reference

12 December 2020

EVIDENCE FOR A ROLE OF DOPAMINE IN EXTRAPYRAMIDAL FUNCTIONS

1 reference

12 December 2020

1 reference

12 December 2020

Five year follow-up of treatment with trihexyphenidyl (artane); outcome in four hundred eleven cases of paralysis agitans.

1 reference

12 December 2020

Nonmotor fluctuations in patients with Parkinson's disease

1 reference

12 December 2020

Dopamine (3-hydroxytyramine) in the central nervous system and its relation to the Parkinson syndrome in man

1 reference

12 December 2020

1 reference

12 December 2020

Effect of deprenyl on the progression of disability in early Parkinson's disease

1 reference

12 December 2020

Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group

1 reference

12 December 2020

Identifiers

DOI

10.1177/1756285609339383

1 reference

2 August 2017

1 reference

2 August 2017

1 reference

PubMed ID

21180628